Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Other current assets consisted of the following as of September 30, 2020 and December 31, 2019:

	September 30, 2020		December 31, 2019
	(unaudited)
Lab supply inventory		2,423		1,825
Prepaid expenses		489		971
Funds in escrow		-		888
Letter of credit		350		-
Due from CGI		525		92
Other		74		75
Total other current assets	$	3,861	$	3,851

Schedule of Basic and Diluted Net Loss Per Share

A reconciliation of the number of shares of common stock, par value $0.01 per share, used in the calculation of basic and diluted loss per share for the three- and nine-month periods ended September 30, 2020 and 2019 is as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2020		2019		2020		2019
	(unaudited)				(unaudited)
Basic weighted average number of common shares		4,038		3,820		4,025		3,717
Potential dilutive effect of stock-based awards		-		-		-		-
Diluted weighted average number of common shares		4,038		3,820		4,025		3,717

Schedule of Computation of Dilutive Securities

The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 shares for the three- and nine-months ended September 30, 2020, and the following outstanding stock-based awards and warrants, were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2020		2019		2020		2019
	(unaudited)				(unaudited)
Options		878		394		878		394
Stock-settled stock appreciation rights (SARs)		-		2		-		2
Restricted stock units (RSUs)		28		54		28		54
Warrants		1,405		1,420		1,405		1,420
		2,311		1,870		2,311		1,870